Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
First Claim
Patent Images
1. A mixture of conjugates each comprising a growth hormone drug coupled to an oligomer that comprises a polyalkylene glycol moiety, said mixture having a molecular weight distribution with a standard deviation of less than about 22 Daltons.
3 Assignments
0 Petitions
Accused Products
Abstract
A mixture of conjugates in which each conjugate in the mixture comprises a growth hormone drug coupled to an oligomer that includes a polyalkylene glycol moiety is disclosed.
-
Citations
67 Claims
- 1. A mixture of conjugates each comprising a growth hormone drug coupled to an oligomer that comprises a polyalkylene glycol moiety, said mixture having a molecular weight distribution with a standard deviation of less than about 22 Daltons.
-
28. A method of treating growth hormone deficiency in a subject in need of such treatment, said method comprising:
administering an effective amount of a mixture of conjugates each comprising a growth hormone drug coupled to an oligomer that comprises a polyalkylene glycol moiety, said mixture having a molecular weight distribution with a standard deviation of less than about 22 Daltons to the patient to treat the growth hormone deficiency.
-
29. A method of accelerating the growth rate of an animal, said method comprising:
administering to the animal a mixture of conjugates each comprising a growth hormone drug coupled to an oligomer that comprises a polyalkylene glycol moiety, said mixture having a molecular weight distribution with a standard deviation of less than about 22 Daltons, in an amount sufficient to accelerate the animal'"'"'s growth rate.
- 30. A substantially monodispersed mixture of conjugates, each conjugate comprising a growth hormone drug coupled to an oligomer that comprises a polyalkylene glycol moiety.
- 40. A substantially monodispersed mixture of conjugates, each conjugate comprising human growth hormone covalently coupled to an oligomer that comprises a uniform polypropylene glycol moiety having at least 7 polypropylene glycol subunits.
- 42. A mixture of conjugates each comprising a growth hormone drug coupled to a polymer having a polyalkylene glycol moiety, wherein the mixture has a dispersity coefficient (DC) greater than 10,000 where
-
49. A mixture of conjugates in which each conjugate:
-
comprises a growth hormone drug coupled to an oligomer; and
has the same number of polyalkylene glycol subunits. - View Dependent Claims (50, 51, 52, 53)
-
-
54. A mixture of conjugates in which each conjugate has the same molecular weight and has the formula:
-
Growth Hormone Drug-[—
B—
Lh—
Gi—
Rm—
G′
J—
R′
n—
G″
k—
T]p
(A)wherein;
B is a bonding moiety;
L is a linker moiety;
G, G′ and
G″
are individually selected spacer moieties;
R is a lipophilic moiety and R′
is a polyalkylene glycol moiety, or R′
is the lipophilic moiety and R is the polyalkylene glycol moiety;
T is a terminating moiety;
h, i, j, k, m and n are individually 0 or 1, with the proviso that when R is the polyalkylene glycol moiety;
m is 1, and when R′
is the polyalkylene glycol moiety, n is 1; and
p is an integer from 1 to the number of nucleophilic residues on the growth hormone drug. - View Dependent Claims (55, 56, 57, 58)
-
-
59. A process for synthesizing a substantially monodispersed mixture of conjugates each conjugate comprising a growth hormone drug coupled to an oligomer that comprises a polyethylene glycol moiety, said process comprising:
-
reacting a substantially monodispersed mixture comprising compounds having the structure of Formula I;
R1(OC2H4)m—
O−
X+
(I)wherein R1 is H or a lipophilic moiety;
m is from 1 to 25; and
X+ is a positive ion,with a substantially monodispersed mixture comprising compounds having the structure of Formula II;
R2(OC2H4)n—
OMs
(II)wherein R2 is H or a lipophilic moiety; and
n is from 1 to 25, under conditions sufficient to provide a substantially monodispersed mixture comprising polymers having the structure of Formula III;
R2(OC2H4)m+n—
OR1
(III);
activating the substantially monodispersed mixture comprising polymers of Formula III to provide a substantially monodispersed mixture of activated polymers capable of reacting with a growth hormone drug; and
reacting the substantially monodispersed mixture of activated polymers with a substantially monodispersed mixture of growth hormone drugs under conditions sufficient to provide a substantially monodispersed mixture of conjugates each comprising a growth hormone drug coupled to an oligomer that comprises a polyethylene glycol moiety with m+n subunits. - View Dependent Claims (60, 61, 62, 63, 64, 65, 66, 67)
-
Specification